HMB for Muscle: Who Might Benefit and What Is Uncertain

β-hydroxy-β-methylbutyrate (HMB) is a metabolite of leucine. It has been studied as a supplement intended to support muscle retention, recovery, or training adaptation. The evidence does not support presenting it as a routine muscle-building requirement for healthy lifters.

The population matters

HMB may be more plausible when muscle loss or low intake is a concern: older adults, people returning from inactivity, or people undergoing a demanding energy-restriction or rehabilitation period. That is a different question from whether a well-fed, resistance-trained adult gains more muscle by adding HMB to a good programme.

A 2026 meta-analysis of 13 randomized trials in adults aged 50 and older found no significant additional benefit of HMB plus resistance training for muscle mass, fat mass, or strength. The authors concluded that HMB could not be recommended routinely for people able to undertake structured exercise (Wang et al.).

A separate 2025 meta-analysis found modest or borderline effects for handgrip strength and physical-function scores, but no significant improvement in appendicular lean mass, muscle quality, fat mass, or body weight; half of its trials were rated high risk of bias (García-Alonso et al.). These results are not a clean muscle-hypertrophy win.

What about trained lifters?

Older trials and reviews have produced mixed results, often with small samples and different training statuses. Effects reported in untrained or clinical populations cannot be assumed to apply to a lifter already consuming adequate protein and progressing resistance exercise. An acute change in protein turnover or a marker of muscle damage is not the same as a larger long-term muscle cross-section.

Mechanistic claims that HMB “blocks breakdown” or “activates mTOR” describe pathways, not guaranteed outcomes. The practical question is whether adding it improves a meaningful endpoint beyond training, food, and sleep. Current evidence does not justify calling HMB a replacement for complete protein or creatine.

Dose and product claims

Studies often use a fixed daily dose of HMB, but that describes the intervention being tested—not an individually validated prescription. Products differ in calcium-HMB, free-acid HMB, serving size, testing, and cost. Do not infer that a larger dose is better or that timing around the workout creates a special anabolic window.

If a clinician or dietitian suggests HMB during illness, recovery, or poor intake, follow that plan. Consider medication, kidney or liver disease, pregnancy, and the total supplement load before adding it. Stop if adverse effects or cost outweigh a measurable reason to continue.

A sensible decision rule

1. Confirm that calories and complete protein are adequate for the goal.
2. Keep resistance training appropriate to ability and medical context.
3. Define the problem HMB is supposed to solve—strength, function, intake, or recovery.
4. Use a time-limited, single-variable trial only when the potential benefit justifies the cost.
5. Stop if the outcome does not improve or if the supplement adds complexity without value.

Bottom line

HMB remains a context-dependent supplement, not a universal hypertrophy tool. The newest older-adult evidence does not support routine use alongside structured resistance training, while small functional signals in some analyses deserve further study. Prioritize training and complete protein, and reserve HMB for a clearly defined situation with appropriate professional input.

Related reading

• Protein and muscle growth
• Protein during a calorie deficit
• The evidence for creatine

Limits of the evidence

HMB trials vary in age, health, training status, protein intake, formulation, dose, and outcome. Acute protein-turnover studies and older-adult function studies cannot establish a universal effect in trained lifters.

Sources

• HMB with resistance training in older adults. 2026 comprehensive meta-analysis; no routine body-composition or strength benefit.
• HMB, muscle quality, body composition, and function. 2025 systematic review and meta-analysis; high risk of bias in half of trials.
• HMB in trained and competitive athletes. Earlier meta-analysis with population-specific limitations.
• HMB and resistance exercise in young subjects. Systematic review and meta-analysis; context for null and mixed findings.